Brief: Lineage Cell Therapeutics And Cancer Research UK Report Phase 1 Study Results With Vac2

Lineage Cell Therapeutics

24/07/2023 13:44

July 24 (Reuters) - Lineage Cell Therapeutics Inc
 LCTX.A :
    * LINEAGE CELL THERAPEUTICS AND CANCER RESEARCH UK REPORT
TOPLINE
PHASE 1 STUDY RESULTS WITH VAC2 FOR THE TREATMENT OF ADVANCED
NON-SMALL CELL LUNG CANCER
    * LINEAGE CELL THERAPEUTICS INC - NO PATIENTS HAD TREATMENT
EMERGENT SERIOUS ADVERSE EVENTS AND ALL PATIENTS COMPLETED PER
PROTOCOL VACCINATION
    * LINEAGE CELL THERAPEUTICS INC - ANTIGEN-LOADED VAC2
PRODUCT
CANDIDATE APPEARED TO BE WELL TOLERATED IN ALL TREATED PATIENTS

Source text for Eikon:  ID:nBw9fN5xra 
Further company coverage:  LCTX.A 

 ((Reuters.Briefs@thomsonreuters.com;))